Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Revance Therapeutics, Inc. - Common Stock (NQ:RVNC)

3.650 UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 3.650
Bid (Size) 3.650 (47)
Ask (Size) 3.660 (542)
Prev. Close 3.650
Today's Range 3.650 - 3.650
52wk Range 2.395 - 6.650
Shares Outstanding 71,829,718
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
REVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Revance Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioAge, IIPR, FTAI, and Revance and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Performance

YTD
+19.3%
+19.3%
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
+19.3%
+19.3%
1 Year
+42.0%
+42.0%

More News

Read More
RVNC DEADLINE TOMORROW: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important March 4 Deadline in Securities Class Action – RVNC
From The Rosen Law Firm PA
Via GlobeNewswire
SHAREHOLDER ALERT: Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Revance Therapeutics, Inc. (RVNC) - Deadline is March 4, 2025
Via NewMediaWire
Topics Lawsuit
SHAREHOLDER ALERT: Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Revance Therapeutics, Inc. (RVNC) - Deadline is March 4, 2025
Via TheNewswire.com
Topics Lawsuit
Rosen Law Firm Urges Revance Therapeutics, Inc. (NASDAQ: RVNC) Stockholders to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Revance Therapeutics, Inc. (RVNC) - Deadline is March 4, 2025
Via NewMediaWire
Topics Lawsuit
INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Revance Therapeutics, Inc. (RVNC) - Deadline is March 4, 2025
Via TheNewswire.com
Topics Lawsuit
RVNC DEADLINE ALERT: Kirby McInerney LLP Alerts Revance Therapeutics, Inc. Investors of Important Lead Plaintiff Deadline in Class Action Lawsuit
From Kirby McInerney LLP
Via Business Wire
Lead Plaintiff Deadline is March 4, 2025 for Investors of Revance Therapeutics, Inc. (RVNC) - Contact Kaplan Fox
Via NewMediaWire
Topics Lawsuit
Lead Plaintiff Deadline is March 4, 2025 for Investors of Revance Therapeutics, Inc. (RVNC) - Contact Kaplan Fox
Via TheNewswire.com
Topics Lawsuit
Kaplan Fox Alerts Investors of Revance Therapeutics to the Lead Plaintiff Deadline on March 4, 2025
Via NewMediaWire
Topics Lawsuit
Kaplan Fox Alerts Investors of Revance Therapeutics to the Lead Plaintiff Deadline on March 4, 2025
Via TheNewswire.com
Topics Lawsuit
Securities Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC) - Contact Kaplan Fox Before Deadline on March 4, 2025
Via NewMediaWire
Topics Lawsuit
Securities Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC) - Contact Kaplan Fox Before Deadline on March 4, 2025
Via TheNewswire.com
Topics Lawsuit
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioAge, Nextracker, FTAI, and Revance and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Revance Therapeutics, Inc. Class Action Lawsuit Alert: Johnson Fistel Announces Shareholders with Losses Should Contact the Law Firm for More Information
From Johnson Fistel, LLP
Via Business Wire
RVNC STOCK NEWS: Robbins LLP Reminds Revance Therapeutics, Inc. Investors of the Pending Lead Plaintiff Deadline – March 4, 2025
From Robbins LLP
Via GlobeNewswire
RVNC DEADLINE ALERT: Revance Therapeutics Investors Are Encouraged to Contact Kaplan Fox Before Lead Plaintiff Deadline on March 4, 2025
Via NewMediaWire
Topics Lawsuit
RVNC DEADLINE ALERT: Revance Therapeutics Investors Are Encouraged to Contact Kaplan Fox Before Lead Plaintiff Deadline on March 4, 2025
Via TheNewswire.com
Topics Lawsuit
REVANCE THERAPEUTICS INVESTOR ALERT: Kaplan Fox Alerts Investors of a Class Action Deadline on March 4, 2025
Via NewMediaWire
Topics Lawsuit
REVANCE THERAPEUTICS INVESTOR ALERT: Kaplan Fox Alerts Investors of a Class Action Deadline on March 4, 2025
Via TheNewswire.com
Topics Lawsuit
RVNC SHAREHOLDER ALERT: Deadline to Lead in Securities Fraud Lawsuit Against Revance Therapeutics, Inc. (RVNC) is March 4, 2025 - Contact Kaplan Fox
Via TheNewswire.com
Topics Fraud Lawsuit
RVNC SHAREHOLDER ALERT: Deadline to Lead in Securities Fraud Lawsuit Against Revance Therapeutics, Inc. (RVNC) is March 4, 2025 - Contact Kaplan Fox
Via NewMediaWire
Topics Fraud Lawsuit
Kaplan Fox Alerts Revance Therapeutics Investors to a Securities Class Action Lawsuit - Deadline is March 4, 2025
Via NewMediaWire
Topics Lawsuit

Frequently Asked Questions

Is Revance Therapeutics, Inc. - Common Stock publicly traded?
Yes, Revance Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Revance Therapeutics, Inc. - Common Stock trade on?
Revance Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Revance Therapeutics, Inc. - Common Stock?
The ticker symbol for Revance Therapeutics, Inc. - Common Stock is RVNC on the Nasdaq Stock Market
What is the current price of Revance Therapeutics, Inc. - Common Stock?
The current price of Revance Therapeutics, Inc. - Common Stock is 3.650
When was Revance Therapeutics, Inc. - Common Stock last traded?
The last trade of Revance Therapeutics, Inc. - Common Stock was at 02/05/25 04:00 PM ET
What is the market capitalization of Revance Therapeutics, Inc. - Common Stock?
The market capitalization of Revance Therapeutics, Inc. - Common Stock is 262.18M
How many shares of Revance Therapeutics, Inc. - Common Stock are outstanding?
Revance Therapeutics, Inc. - Common Stock has 262M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.